LDHA and glioblastoma: A better understanding of LDHA-enriched EV subpopulation as a potential 'metabolic switch' is needed to function as a non-invasive biomarker and therapeutic target, providing novel insights for GBM diagnosis and preventing recurrence in future clinical translation.